Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus capecitabine and oxaliplatin as neoadjuvant/perioperative therapy for gastric or gastroesophageal junction adenocarcinoma
ChiCTR2100053840Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Pathological complete response rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100053840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053840.